Artenimol
As of the edition of 20 October 2026, Artenimol is a small molecule: marketed, first approved in 2011 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Eurartesim
- First approved
- 27 October 2011 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Alfasigma
- Registered trials
- 21, 1 stopped early
- Disease areas
- Infections; Cancer; Skin and connective tissue; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 5 | 4 | 1 | 0 |
| Phase 2 | 9 | 4 | 3 | 1 |
| Phase 3 | 3 | 2 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 21 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Alfasigma | Applicant and Lead sponsor of trials | 2011 to now |